Baird on Neurocrine Bio's Soleno deal: Incrementally positive on acquisition
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $186.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented: "Incrementally ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
